Wim Zhong
Director, Protein Sciences and Head of Structural Biology at THEON Therapeutics - Cambridge, MA, us
Wim Zhong's Colleagues at THEON Therapeutics
Wim Zhong's Contact Details
N/A
THEON Therapeutics
Wim Zhong's Company Details
tRNA Is Translating The World™Theonys is a patient-focused drug discovery company developing small-molecule correctors of RNA pathobiology. We are advancing a new understanding of how tRNA dysfunction drives the selective translation of multiple genetic programs that cause human disease. Our drug discovery pipeline is focused on novel targets with mechanistic roles in the translational dysfunction that drives cancer, chronic inflammation and rare immunometabolic disease — opening the door to an entirely new targeted approach to treating complex, multigenic diseases. Our mission is to leverage deep insights into gene regulation at the level of translation to expand the therapeutic universe for serious diseases. With this in mind, we built our proprietary METTLVERSE™ Platform to aid the discovery of selective CONTEXT™ (CONTrolled EXpression Technology) Controllers: small-molecule modulators that functionally regulate 98% of the human genome. Currently, we are focused on developing CONTEXT™ Controllers to improve treatment efficacy and lower the risk of resistance in cancer by selectively stopping the translation of disease-causing proteins across multiple established oncogenic pathways. Theonys is working to bring the treatment of historically intractable, genetically driven diseases into the scope of medicinal chemistry.Founded by an experienced team of drug hunters at MIT and Harvard in 2020, Theonys is proudly backed by Leaps (Bayer), Xora Innovation (Temasek), Humboldt Fund, Emerson Collective and Alexandria Venture Investments.